

Report Information

More information from: <https://www.marketresearchfuture.com/reports/hypothyroidism-market-6958>

Hypothyroidism Market Research Report – Forecast till 2032

Report / Search Code: MRFR/Pharma/5493-HCR

Publish Date: March, 2024

[Request Sample](#)

Price	1-user PDF : \$ 4455.0	Site PDF : \$ 5355.0	Enterprise PDF : \$ 6525.0
-------	------------------------	----------------------	----------------------------

Description:

Global Hypothyroidism Market Overview

Hypothyroidism Market Size was valued at USD 2.1 Billion in 2022. The hypothyroidism market industry is projected to grow from USD 2.19 Billion in 2023 to USD 3.14 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.60% during the forecast period (2023 - 2032). Increases in the prevalence of thyroid gland disorders, the number of disease awareness campaigns, particularly in developing nations, and the creation of potent drug combinations to treat thyroid disorders are the key market drivers enhancing the market growth. Additionally, the vast population of undiagnosed patients because thyroid problems are asymptomatic helps provide new opportunities for market expansion throughout the projected period.

[Hypothyroidism Market Overview](#)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Hypothyroidism Market Trends

Rising prevalence of thyroid disorder is driving the market growth

Market CAGR for hypothyroidism is driven by the rising number of thyroid disorders. Due to the increased prevalence of thyroid gland problems, the market for treatments for these conditions is anticipated to expand rapidly. Thyroid therapies are becoming increasingly popular on the market, both in developed and developing nations. The vendors are concentrating on the underdeveloped rising markets in the Middle East, Africa, China, and India. About 10% of Indian adults had hypothyroidism as of October 2020. Research indicates that women are more inclined to acquire hypothyroidism between the ages of 46 and 54. Several domestic and international suppliers target high-potential rising nations, including Novartis AG, Pfizer Inc., and Merck & Co., Inc. The aforementioned elements will accelerate market expansion within the anticipated time frame.

Around 5.5%–6% of people worldwide suffer from subclinical thyroid problems. Due to a lack of knowledge, 50% of people with thyroid issues go undetected. Governmental and non-governmental organizations are increasingly initiating public awareness campaigns to raise knowledge of rapid diagnosis and treatment of thyroid gland problems. These programs aim to inform the public about quickly detecting early symptoms that might evolve into complex thyroid disorders. For instance, the AACE began its UP To Here Campaign in January 2020. The campaign's goal is to raise public awareness of thyroid conditions. These camps were designed to inform attendees of the higher risk of acquiring thyroid disorders, their prevalence, and the availability of programs to educate and avoid the condition. International Thyroid Awareness Week is observed each November around the world. The aforementioned elements will accelerate market expansion within the anticipated time frame. Thus, driving the hypothyroidism market revenue.

Hypothyroidism Market Segment Insights

Hypothyroidism Type Insights

The hypothyroidism market segmentation, based on type, includes primary hypothyroidism, secondary hypothyroidism, and tertiary hypothyroidism. The primary hypothyroidism segment dominated the market, accounting for 46.5% of market revenue (1.00 Billion). Low blood thyroid hormone levels resulting from thyroid gland degeneration are known as primary hypothyroidism. Fatigue, sadness, constipation, and modest weight gain are among the nonspecific symptoms of primary hypothyroidism that are typically present. Subclinical illness is typical. Physical examination may reveal bradycardia, thick tongue, swollen eyelids, and dry skin. Furthermore, in 2022, tertiary hypothyroidism was the fastest-growing sector in the market. In tertiary hypothyroidism, insufficient thyrotropin-releasing hormone (TRH) production from the hypothalamus produces insufficient thyroid stimulating hormone (TSH) release, resulting in insufficient thyroid stimulation. But this is

uncommon. Iodine deficiency continues to be the leading contributor to hypothyroidism in the world.

Figure 1 Hypothyroidism Market, by Type, 2022 & 2032 (USD Billion)

Hypothyroidism Market by Type

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Hypothyroidism Diagnosis & Treatment Insights

The hypothyroidism market segmentation, based on diagnosis & treatment, includes diagnosis and treatment. In 2022, the diagnosis segment dominated the market. The need for an efficient diagnostic method for the early detection of thyroid problems has increased due to the increasing prevalence of thyroid illnesses worldwide. Typically, thyroid exams are done to assess thyroid function and look for conditions like hypothyroidism or hyperthyroidism. A blood test is used to quantify TSH, T4, T3, and free T4 in a blood sample to assess the body's quantity of thyroid hormone production. Additionally, the treatment sector acquired a significant share of the market. Due to more doctors prescribing this class of medication ly, this category is anticipated to rise. Liothyronine and Levothyroxine are the two main medication groups used to treat hypothyroidism.

Hypothyroidism Route of Administration Insights

The hypothyroidism market segmentation, based on the route of administration, includes oral and intravenous. The oral segment acquired a major market share in 2022. The oral sector predominated the market due to the creation of new medicines and a strong pipeline. High efficacy, a greater bioavailability rate, and quick medication administration likely drive segment expansion. Drugs with a medium to high oral bioavailability can be effectively administered orally. Oral medicines lessen the need for central lines for administering intravenous drugs, lowering the risk of complications and length of hospital stay. Also, the intravenous segment saw considerable growth. Even for severe hypothyroidism, intramuscular therapy is effective. People with poor compliance brought on by self-neglect, cognitive decline, or inadequate gastric absorption may find it very useful.

Hypothyroidism Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American hypothyroidism market area will dominate this market. One reason for its high revenue share is the existence of efficient healthcare facilities, higher knowledge levels among people, and a wide range of available treatment alternatives. Strategic alliances between pharmaceutical firms and governmental bodies are growing in the region, especially to create generic medications and raise awareness among healthcare professionals.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2 HYPOTHYROIDISM MARKET SHARE BY REGION 2022 (USD Billion)

HYPOTHYROIDISM MARKET SHARE BY REGION

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's hypothyroidism market accounts for the second-largest market share because local producers concentrate on creating low-cost, more effective products. Additionally, due to the lower price of labour and raw materials, overseas investors are making investments in regional businesses. Further, the German hypothyroidism market held the largest market share, and the UK hypothyroidism market was the rapidly growing market in the European region.

The Asia-Pacific Hypothyroidism Market is expected to grow at the fastest CAGR from 2023 to 2032 because of the rising incidence of thyroid cancer, increased consumer awareness, better healthcare infrastructure, and higher disposable money. Emerging nations like China, India, and South Korea are anticipated to expand the hypothyroidism market strongly throughout the forecast period. Moreover, China's hypothyroidism market held the largest market share, and the Indian hypothyroidism market was the rapidly growing market in the Asia-Pacific region.

Hypothyroidism Key Market Players & Competitive Insights

Leading market players are largely investing in research and development to expand their product lines, which will help the hypothyroidism market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The hypothyroidism industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the hypothyroidism industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the hypothyroidism industry has stipulated some of the most important medicinal benefits. Major players in the hypothyroidism industry, including Mylan N.V., Merck & Co., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and others, are funding operations for research and development to boost market demand.

Zydus Lifesciences Limited, originally Cadila Healthcare Limited, is an Indian multinational pharmaceutical business based in Ahmedabad that mostly manufactures generic pharmaceuticals.

The group's product range includes Active Pharmaceutical Ingredients, human formulations, health and wellness goods, and animal health and veterinary products. Among its product brands are Aten, Falcigo, Nucoxia, Levoday, Metascore, and Arzep. In November 2022, Zydus Lifesciences gained FDA permission to market Levothyroxine Sodium injection, which is used to treat thyroid hormone insufficiency. According to a regulatory filing, the company's US-based affiliate has gained preliminary permission from the US Food and Drug Administration (USFDA) to market the pharmaceutical.

Exelixis is a biopharmaceutical company that finds, develops, and commercializes cancer therapies. Its main ingredient, cabozantinib, is sold under the brand names Cometriq and Cabometyx and is utilized for the therapy of patients with metastatic medullary thyroid cancer. In September 2021, Exelixis, Inc. announced that the FDA had approved CABOMETYX (cabozantinib) for the therapy of children aged above 12 years and adults with metastatic or advanced differentiated thyroid cancer that has advanced following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible.

Key Companies in the hypothyroidism market include

- Pfizer Inc.
- AbbVie Inc.
- Merck & Co.
- ALLERGAN
- Mylan N.V.
- Erfa Canada Inc
- Novartis AG
- GlaxoSmithKline plc
- RLC Labs

Hypothyroidism Industry Developments

January 2023 Sernova Corp., a clinical-stage firm and cell therapy leader, revealed today progress in its thyroid cell therapy program, one of three cell therapy development programs utilizing the firm's unique Cell Pouch System™. The Company demonstrated in a preclinical proof of concept study that auto-transplantation of thyroid tissue into the Cell Pouch could compensate for thyroid gland removal (complete thyroidectomy), restoring normal thyroid hormone levels in an animal model.

November 2021 Bloom Diagnostics, a Swiss medtech startup, has created the Bloom Thyroid Test to aid in detecting hypothyroidism. Bloom has created an intelligent self-testing system for a variety of medical ailments. The single-use kit can detect thyroid dysfunction in individuals by testing them for thyroid-stimulating hormone (TSH).

Hypothyroidism Market Segmentation

Hypothyroidism Type Outlook

- Primary Hypothyroidism
- Secondary Hypothyroidism
- Tertiary Hypothyroidism

Hypothyroidism Diagnosis & Treatment Outlook

- Diagnosis
- Treatment

Hypothyroidism Route of Administration Outlook

- Oral
- Intravenous

Hypothyroidism Regional Outlook

- North America
 - US
 - Canada
- Europe
 - Germany
 - France
 - UK
 - Italy
 - Spain
 - Rest of Europe
- Asia-Pacific
 - China
 - Japan
 - India
 - Australia
 - South Korea
 - Australia
 - Rest of Asia-Pacific
- Rest of the World
 - Middle East
 - Africa
 - Latin America

Table of Content:

Contents

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Product Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter's Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hypothyroidism Market, by Type of Hypothyroidism

6.1 Introduction

6.2 Primary Hypothyroidism	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
6.3 Secondary Hypothyroidism	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
6.4 Tertiary Hypothyroidism	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
Chapter 7. Global Hypothyroidism Market, by Diagnosis & Treatment	
7.1 Introduction	
7.2 Diagnosis	
7.2.1 Physical Examination	
Market Estimates & Forecast, by Region, 2020–2027	
7.2.2 Blood Tests	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.2.3 Imaging Scan	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.2.4 Others	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.3 Treatment	
7.3.1 Levothyroxine Sodium	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.3.2 Liothyronine	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
7.3.3 Natural Desiccated Thyroid (NDT)	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
Chapter 8. Global Hypothyroidism Market, by Route of Administration	
8.1 Introduction	
8.2 Oral	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
8.3 Intravenous	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
8.4 Others	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
Chapter 9. Global Hypothyroidism Market, by End User	
9.1 Introduction	
9.2 Hospitals	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
9.3 Clinics	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
9.4 Research & Academic Institutes	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
9.5 Others	
Market Estimates & Forecast, by Region, 2020–2027	
Market Estimates & Forecast, by Country, 2020–2027	
Chapter 10. Global Hypothyroidism Market, by Region	
10.1 Introduction	
10.2 Americas	
10.2.1 North America	
10.2.1.1 US	
10.2.1.2 Canada	
10.2.2 South America	
10.3 Europe	
10.3.1 Western Europe	
10.3.1.1 Germany	
10.3.1.2 France	
10.3.1.3 Italy	
10.3.1.4 Spain	
10.3.1.5 UK	
10.3.1.6 Rest of Western Europe	
10.3.2 Eastern Europe	
10.4 Asia-Pacific	
10.4.1 Japan	
10.4.2 China	
10.4.3 India	
10.4.4 Australia	
10.4.5 South Korea	
10.4.6 Rest of Asia-Pacific	
10.5 Middle East & Africa	
10.5.1 Middle East	
10.5.2 Africa	
Chapter 11. Company Landscape	
11.1 Introduction	
11.2 Market Share Analysis	
11.3 Key Development & Strategies	
Chapter 12. Company Profiles	
12.1 PFIZER INC.	
12.1.1 Company Overview	
12.1.2 Product Overview	
12.1.3 Financials Overview	

12.1.4 Key Developments	
12.1.5 SWOT Analysis	
12.2 AbbVie Inc.	
12.2.1 Company Overview	
12.2.2 Product Overview	
12.2.3 Financial Overview	
12.2.4 Key Developments	
12.2.5 SWOT Analysis	
12.3 MERCK & CO., INC.	
12.3.1 Company Overview	
12.3.2 Product Overview	
12.3.3 Financial Overview	
12.3.4 Key Development	
12.3.5 SWOT Analysis	
12.4 ALLERGAN	
12.4.1 Company Overview	
12.4.2 Product Overview	
12.4.3 Financial Overview	
12.4.4 Key Development	
12.4.5 SWOT Analysis	
12.5 Mylan N.V.	
12.5.1 Company Overview	
12.5.2 Product Overview	
12.5.3 Financial overview	
12.5.4 Key Developments	
12.5.5 SWOT Analysis	
12.6 Erfa Canada Inc	
12.6.1 Company Overview	
12.6.2 Product Overview	
12.6.3 Financial Overview	
12.6.4 Key Developments	
12.6.5 SWOT Analysis	
12.7 Novartis AG	
12.7.1 Overview	
12.7.2 Product Overview	
12.7.3 Financial Overview	
12.7.4 Key Developments	
12.7.5 SWOT Analysis	
12.8 GlaxoSmithKline plc	
12.8.1 Overview	
12.8.2 Product Overview	
12.8.3 Financials	
12.8.4 Key Developments	
12.8.5 SWOT Analysis	
12.9 RLC Labs	
12.9.1 Overview	
12.9.2 Product Overview	
12.9.3 Financials	
12.9.4 Key Developments	
12.9.5 SWOT Analysis	
12.10 Others	
Chapter 13 MRFR Conclusion	
13.1 Key Findings	
13.1.1 From CEO's View point	
13.1.2 Unmet Needs of the Market	
13.2 Key Companies to Watch	
13.3 Predictions for the Cannula Industry	

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Hypothyroidism Market Synopsis, 2020–2027	
Table 2 Global Hypothyroidism Market Estimates and Forecast, 2020–2027 (USD Million)	
Table 3 Global Hypothyroidism Market, by Region, 2020–2027 (USD Million)	
Table 4 Global Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 5 Global Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 6 Global Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	
Table 7 Global Hypothyroidism Market, by End User, 2020–2027 (USD Million)	
Table 8 North America: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 9 North America: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 10 North America: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	
Table 11 North America: Hypothyroidism Market, by End User, 2020–2027 (USD Million)	
Table 12 US: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 13 US: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 14 US: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	
Table 15 US: Hypothyroidism Market, by End User, 2020–2027 (USD Million)	
Table 16 Canada: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 17 Canada: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 18 Canada: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	
Table 19 Canada: Hypothyroidism Market, by End User, 2020–2027 (USD Million)	
Table 20 South America: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 21 South America: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 22 South America: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	
Table 23 South America: Hypothyroidism Market, by End User, 2020–2027 (USD Million)	
Table 24 Europe: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 25 Europe: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 26 Europe: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	
Table 27 Europe: Hypothyroidism Market, by End User, 2020–2027 (USD Million)	
Table 28 Western Europe: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 29 Western Europe: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 30 Western Europe: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	
Table 31 Western Europe: Hypothyroidism Market, by End User, 2020–2027 (USD Million)	
Table 32 Eastern Europe: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)	
Table 33 Eastern Europe: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)	
Table 34 Eastern Europe: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)	

Table 35 Eastern Europe: Hypothyroidism Market, by End User, 2020–2027 (USD Million)
Table 36 Asia-Pacific: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)
Table 37 Asia-Pacific: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)
Table 38 Asia-Pacific: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)
Table 39 Asia-Pacific: Hypothyroidism Market, by End User, 2020–2027 (USD Million)
Table 40 Middle East & Africa: Hypothyroidism Market, by Type of Hypothyroidism, 2020–2027 (USD Million)
Table 41 Middle East & Africa: Hypothyroidism Market, by Diagnosis & Treatment, 2020–2027 (USD Million)
Table 42 Middle East & Africa: Hypothyroidism Market, by Route of Administration, 2020–2027 (USD Million)
Table 43 Middle East & Africa: Hypothyroidism Market, by End User, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Market Structure for Global Hypothyroidism Market
Figure 3 Market Dynamics for Global Hypothyroidism Market
Figure 4 Global Hypothyroidism Market Share, by Type of Hypothyroidism, 2020
Figure 5 Global Hypothyroidism Market Share, by Diagnosis & Treatment, 2020
Figure 6 Global Hypothyroidism Market Share, by Route of Administration, 2020
Figure 7 Global Hypothyroidism Market Share, by End User, 2020
Figure 8 Global Hypothyroidism Market Share, by Region, 2020
Figure 9 North America: Hypothyroidism Market Share, by Country, 2020
Figure 10 Europe: Hypothyroidism Market Share, by Country, 2020
Figure 11 Asia-Pacific: Hypothyroidism Market Share, by Country, 2020
Figure 12 Middle East & Africa: Hypothyroidism Market Share, by Country, 2020
Figure 13 Global Hypothyroidism Market: Company Share Analysis, 2020 (%)
Figure 14 PFIZER INC.: Key Financials
Figure 15 PFIZER INC.: Segmental Revenue
Figure 16 PFIZER INC.: Geographical Revenue
Figure 17 AbbVie Inc.: Key Financials
Figure 18 AbbVie Inc.: Segmental Revenue
Figure 19 AbbVie Inc.: Geographical Revenue
Figure 20 MERCK & CO., INC.: Key Financials
Figure 21 MERCK & CO., INC.: Segmental Revenue
Figure 22 MERCK & CO., INC.: Geographical Revenue
Figure 23 ALLERGAN: Key Financials
Figure 24 ALLERGAN: Segmental Revenue
Figure 25 ALLERGAN: Geographical Revenue
Figure 26 Mylan N.V.: Key Financials
Figure 27 Mylan N.V.: Segmental Revenue
Figure 28 Mylan N.V.: Geographical Revenue
Figure 29 Erfa Canada Inc: Key Financials
Figure 30 Erfa Canada Inc: Segmental Revenue
Figure 31 Erfa Canada Inc: Geographical Revenue
Figure 32 Novartis AG: Key Financials
Figure 33 Novartis AG: Segmental Revenue
Figure 34 Novartis AG: Geographical Revenue
Figure 35 GlaxoSmithKline plc: Key Financials
Figure 36 GlaxoSmithKline plc: Segmental Revenue
Figure 37 GlaxoSmithKline plc: Geographical Revenue
Figure 38 RLC Labs: Key Financials
Figure 39 RLC Labs: Segmental Revenue
Figure 40 RLC Labs: Geographical Revenue
Figure 41 McKesson Medical-Surgical Inc.: Key Financials
Figure 42 McKesson Medical-Surgical Inc.: Segmental Revenue
Figure 43 McKesson Medical-Surgical Inc.: Geographical Revenue
Figure 44 Harsoria Healthcare Pvt. Ltd.: Key Financials
Figure 45 Harsoria Healthcare Pvt. Ltd.: Segmental Revenue
Figure 46 Harsoria Healthcare Pvt. Ltd.: Geographical Revenue
Figure 47 ISPG Inc.: Key Financials
Figure 48 ISPG Inc.: Segmental Revenue
Figure 49 ISPG Inc.: Geographical Revenue
Figure 50 ILIFE MEDICAL DEVICES PRIVATE LIMITED (INDIA): Key Financials
Figure 51 ILIFE MEDICAL DEVICES PRIVATE LIMITED (INDIA): Segmental Revenue
Figure 52 ILIFE MEDICAL DEVICES PRIVATE LIMITED (INDIA): Geographical Revenue
Figure 53 Denex International: Key Financials
Figure 54 Denex International: Segmental Revenue
Figure 55 Denex International: Geographical Revenue
Figure 56 BD: Key Financials
Figure 57 BD: Segmental Revenue
Figure 58 BD: Geographical Revenue